BioCentury
ARTICLE | Management Tracks

McCracken named CEO at Evonetix

Plus Pirzkall becomes CMO at Asher, and updates from Domain, Syndax, Ascletis and more

June 14, 2022 1:09 AM UTC

U.K.-based DNA synthesis company Evonetix Ltd. named Colin McCracken CEO. McCracken joins from Fluidigm Corp. (NASDAQ:FLDM), where he was SVP and chief commercial officer. Previously, he was VP of sales at Thermo Fisher Scientific Inc. (NYSE:TMO), VP and head of European sales at Life Technologies Inc., and national sales manager at Qiagen N.V. (NYSE:QGEN; Xetra:QIA). Evonetix is developing semiconductor-based DNA synthesis platform. 

Andrea Pirzkall joined Asher Biotherapeutics Inc. as CMO. Pirzkall was most recently CMO at Replimune Group Inc. South San Francisco-based Asher is developing immunotherapies via its cis-targeting platform for cancer, autoimmune and infectious diseases...